Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

579000 Tamoxifen Citrate - CAS 54965-24-1 - Calbiochem

579000
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
54965-24-1C₂₆H₂₉NO · C₆H₈O₇

Products

Catalogue NumberPackaging Qty/Pack
579000-100MG Sklená flaša 100 mg
Description
OverviewA potent synthetic anti-estrogenic agent. A cell-permeable and reversible inhibitor of protein kinase C (IC50 = 10 µM). Induces apoptosis in human malignant glioma cell lines and inhibits prostate cancer cell growth by induction of p21 protein.
Catalogue Number579000
Brand Family Calbiochem®
SynonymsEstrogen Receptor Signaling Regulator I
References
ReferencesRohlff, C., et al. 1998. Prostate 37, 51.
Couldwell, W.J., et al. 1994. FEBS Lett. 345, 43.
Baltuch, G.H., et al. 1993. Neurosurgery 33, 495.
Powis, G. 1991. Trends Pharmacol. Sci. 12, 188.
Issandou, M., et al. 1990. Cancer Res. 50, 5845.
O’Brian, C.A., et al. 1985. Cancer Res. 45, 2462.
Product Information
CAS number54965-24-1
ATP CompetitiveN
FormWhite to off-white powder
Hill FormulaC₂₆H₂₉NO · C₆H₈O₇
Chemical formulaC₂₆H₂₉NO · C₆H₈O₇
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetPKC
Primary Target IC<sub>50</sub>10 µM against protein kinase C
Purity≥99% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSKH2387000
Safety Information
R PhraseR: 22-45-60-61-64

Harmful if swallowed.
May cause cancer.
May impair fertility.
May cause harm to the unborn child.
May cause harm to breastfed babies.
S PhraseS: 36/37/39-45

Wear suitable protective clothing, gloves and eye/face protection.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful & Carcinogenic / Teratogenic
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
579000-100MG 04055977265934

Documentation

Tamoxifen Citrate - CAS 54965-24-1 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

Tamoxifen Citrate - CAS 54965-24-1 - Calbiochem Certificates of Analysis

TitleLot Number
579000

References

Reference overview
Rohlff, C., et al. 1998. Prostate 37, 51.
Couldwell, W.J., et al. 1994. FEBS Lett. 345, 43.
Baltuch, G.H., et al. 1993. Neurosurgery 33, 495.
Powis, G. 1991. Trends Pharmacol. Sci. 12, 188.
Issandou, M., et al. 1990. Cancer Res. 50, 5845.
O’Brian, C.A., et al. 1985. Cancer Res. 45, 2462.

Brochure

Title
Caspases and other Apoptosis Related Tools Brochure
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision11-January-2010 RFH
SynonymsEstrogen Receptor Signaling Regulator I
DescriptionA potent synthetic anti-estrogen. A cell-permeable and reversible inhibitor of protein kinase C (IC50 = 10 µM). Induces apoptosis in human malignant glioma cell lines.
FormWhite to off-white powder
CAS number54965-24-1
RTECSKH2387000
Chemical formulaC₂₆H₂₉NO · C₆H₈O₇
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityEthanol (5 mg/ml), Methanol (5 mg/ml), or sparingly soluble in H₂O
Storage +2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Harmful & Carcinogenic / Teratogenic
Merck USA index14, 9048
ReferencesRohlff, C., et al. 1998. Prostate 37, 51.
Couldwell, W.J., et al. 1994. FEBS Lett. 345, 43.
Baltuch, G.H., et al. 1993. Neurosurgery 33, 495.
Powis, G. 1991. Trends Pharmacol. Sci. 12, 188.
Issandou, M., et al. 1990. Cancer Res. 50, 5845.
O’Brian, C.A., et al. 1985. Cancer Res. 45, 2462.